Lb Pharmaceuticals (LBRX) Total Non-Current Liabilities (2024 - 2026)

Lb Pharmaceuticals has reported Total Non-Current Liabilities for 3 years, with the latest figure at $13.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $13.6 million; the trailing twelve-month figure through Mar 2026 stood at $13.6 million (changed N/A YoY), and the FY2025 full-year result was $10.3 million, down 9.22% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $13.6 million, up from $10.3 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $13.6 million in Q1 2026, with the low at $9.6 million in Q3 2025.
• Average Total Non-Current Liabilities over 3 years is $11.2 million, with a median of $10.8 million recorded in 2024.
• Peak annual rise in Total Non-Current Liabilities reached 9.22% in 2025, while the deepest fall reached 9.22% in 2025.
• Tracing LBRX's Total Non-Current Liabilities over 3 years: stood at $11.3 million in 2024, then dropped by 9.22% to $10.3 million in 2025, then jumped by 32.73% to $13.6 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $13.6 million (Q1 2026), $10.3 million (Q4 2025), and $9.6 million (Q3 2025), per Business Quant data.

Peer Comparison